United States Central Nervous System Disorders Therapeutics Market Report 2016

October 2016 | 114 pages | ID: U2C1BF9D07AEN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Central Nervous System Disorders Therapeutics

Revenue, means the sales value of Central Nervous System Disorders Therapeutics

This report studies sales (consumption) of Central Nervous System Disorders Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Novartis
• AB Science
• AbbVie
• Archer Pharmaceuticals
• F. Hoffmann-La Roche
• UCB
• SK Biopharmaceuticals
• Shire
• Sanofi
• Merck
• Mitsubishi Tanabe

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Central Nervous System Disorders Therapeutics in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States Central Nervous System Disorders Therapeutics Market Report 2016

1 CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Central Nervous System Disorders Therapeutics
1.2 Classification of Central Nervous System Disorders Therapeutics
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Central Nervous System Disorders Therapeutics
  1.3.1 Application 1
  1.3.2 Application 2
  1.3.3 Application 3
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Central Nervous System Disorders Therapeutics (2011-2021)
  1.4.1 United States Central Nervous System Disorders Therapeutics Sales and Growth Rate (2011-2021)
  1.4.2 United States Central Nervous System Disorders Therapeutics Revenue and Growth Rate (2011-2021)

2 UNITED STATES CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS COMPETITION BY MANUFACTURERS

2.1 United States Central Nervous System Disorders Therapeutics Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Central Nervous System Disorders Therapeutics Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Central Nervous System Disorders Therapeutics Average Price by Manufactures (2015 and 2016)
2.4 Central Nervous System Disorders Therapeutics Market Competitive Situation and Trends
  2.4.1 Central Nervous System Disorders Therapeutics Market Concentration Rate
  2.4.2 Central Nervous System Disorders Therapeutics Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Central Nervous System Disorders Therapeutics Sales and Market Share by Type (2011-2016)
3.2 United States Central Nervous System Disorders Therapeutics Revenue and Market Share by Type (2011-2016)
3.3 United States Central Nervous System Disorders Therapeutics Price by Type (2011-2016)
3.4 United States Central Nervous System Disorders Therapeutics Sales Growth Rate by Type (2011-2016)

4 UNITED STATES CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Central Nervous System Disorders Therapeutics Sales and Market Share by Application (2011-2016)
4.2 United States Central Nervous System Disorders Therapeutics Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS MANUFACTURERS PROFILES/ANALYSIS

5.1 GlaxoSmithKline
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 GlaxoSmithKline Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Pfizer
  5.2.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Pfizer Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Eli Lilly
  5.3.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Eli Lilly Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Janssen Pharmaceuticals
  5.4.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Janssen Pharmaceuticals Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 Novartis
  5.5.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 Novartis Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 AB Science
  5.6.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 AB Science Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 AbbVie
  5.7.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 AbbVie Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Archer Pharmaceuticals
  5.8.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Archer Pharmaceuticals Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 F. Hoffmann-La Roche
  5.9.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 F. Hoffmann-La Roche Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 UCB
  5.10.2 Central Nervous System Disorders Therapeutics Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 UCB Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 SK Biopharmaceuticals
5.12 Shire
5.13 Sanofi
5.14 Merck
5.15 Mitsubishi Tanabe

6 CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS MANUFACTURING COST ANALYSIS

6.1 Central Nervous System Disorders Therapeutics Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Central Nervous System Disorders Therapeutics

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Central Nervous System Disorders Therapeutics Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Central Nervous System Disorders Therapeutics Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES CENTRAL NERVOUS SYSTEM DISORDERS THERAPEUTICS MARKET FORECAST (2016-2021)

10.1 United States Central Nervous System Disorders Therapeutics Sales, Revenue Forecast (2016-2021)
10.2 United States Central Nervous System Disorders Therapeutics Sales Forecast by Type (2016-2021)
10.3 United States Central Nervous System Disorders Therapeutics Sales Forecast by Application (2016-2021)
10.4 Central Nervous System Disorders Therapeutics Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Central Nervous System Disorders Therapeutics
Table Classification of Central Nervous System Disorders Therapeutics
Figure United States Sales Market Share of Central Nervous System Disorders Therapeutics by Type in 2015
Table Application of Central Nervous System Disorders Therapeutics
Figure United States Sales Market Share of Central Nervous System Disorders Therapeutics by Application in 2015
Figure United States Central Nervous System Disorders Therapeutics Sales and Growth Rate (2011-2021)
Figure United States Central Nervous System Disorders Therapeutics Revenue and Growth Rate (2011-2021)
Table United States Central Nervous System Disorders Therapeutics Sales of Key Manufacturers (2015 and 2016)
Table United States Central Nervous System Disorders Therapeutics Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Central Nervous System Disorders Therapeutics Sales Share by Manufacturers
Figure 2016 Central Nervous System Disorders Therapeutics Sales Share by Manufacturers
Table United States Central Nervous System Disorders Therapeutics Revenue by Manufacturers (2015 and 2016)
Table United States Central Nervous System Disorders Therapeutics Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Central Nervous System Disorders Therapeutics Revenue Share by Manufacturers
Table 2016 United States Central Nervous System Disorders Therapeutics Revenue Share by Manufacturers
Table United States Market Central Nervous System Disorders Therapeutics Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Central Nervous System Disorders Therapeutics Average Price of Key Manufacturers in 2015
Figure Central Nervous System Disorders Therapeutics Market Share of Top 3 Manufacturers
Figure Central Nervous System Disorders Therapeutics Market Share of Top 5 Manufacturers
Table United States Central Nervous System Disorders Therapeutics Sales by Type (2011-2016)
Table United States Central Nervous System Disorders Therapeutics Sales Share by Type (2011-2016)
Figure United States Central Nervous System Disorders Therapeutics Sales Market Share by Type in 2015
Table United States Central Nervous System Disorders Therapeutics Revenue and Market Share by Type (2011-2016)
Table United States Central Nervous System Disorders Therapeutics Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Central Nervous System Disorders Therapeutics by Type (2011-2016)
Table United States Central Nervous System Disorders Therapeutics Price by Type (2011-2016)
Figure United States Central Nervous System Disorders Therapeutics Sales Growth Rate by Type (2011-2016)
Table United States Central Nervous System Disorders Therapeutics Sales by Application (2011-2016)
Table United States Central Nervous System Disorders Therapeutics Sales Market Share by Application (2011-2016)
Figure United States Central Nervous System Disorders Therapeutics Sales Market Share by Application in 2015
Table United States Central Nervous System Disorders Therapeutics Sales Growth Rate by Application (2011-2016)
Figure United States Central Nervous System Disorders Therapeutics Sales Growth Rate by Application (2011-2016)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Figure GlaxoSmithKline Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Pfizer Basic Information List
Table Pfizer Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Eli Lilly Basic Information List
Table Eli Lilly Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eli Lilly Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Janssen Pharmaceuticals Basic Information List
Table Janssen Pharmaceuticals Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Janssen Pharmaceuticals Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Novartis Basic Information List
Table Novartis Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table AB Science Basic Information List
Table AB Science Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table AB Science Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table AbbVie Basic Information List
Table AbbVie Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table AbbVie Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Archer Pharmaceuticals Basic Information List
Table Archer Pharmaceuticals Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Archer Pharmaceuticals Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table F. Hoffmann-La Roche Basic Information List
Table F. Hoffmann-La Roche Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table F. Hoffmann-La Roche Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table UCB Basic Information List
Table UCB Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table UCB Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table SK Biopharmaceuticals Basic Information List
Table SK Biopharmaceuticals Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table SK Biopharmaceuticals Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Shire Basic Information List
Table Shire Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Shire Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Sanofi Basic Information List
Table Sanofi Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Sanofi Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Merck Basic Information List
Table Merck Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Mitsubishi Tanabe Basic Information List
Table Mitsubishi Tanabe Central Nervous System Disorders Therapeutics Sales, Revenue, Price and Gross Margin (2011-2016)
Table Mitsubishi Tanabe Central Nervous System Disorders Therapeutics Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Central Nervous System Disorders Therapeutics
Figure Manufacturing Process Analysis of Central Nervous System Disorders Therapeutics
Figure Central Nervous System Disorders Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Central Nervous System Disorders Therapeutics Major Manufacturers in 2015
Table Major Buyers of Central Nervous System Disorders Therapeutics
Table Distributors/Traders List
Figure United States Central Nervous System Disorders Therapeutics Production and Growth Rate Forecast (2016-2021)
Figure United States Central Nervous System Disorders Therapeutics Revenue and Growth Rate Forecast (2016-2021)
Table United States Central Nervous System Disorders Therapeutics Production Forecast by Type (2016-2021)
Table United States Central Nervous System Disorders Therapeutics Consumption Forecast by Application (2016-2021)